Development of a live, oral, attenuated vaccine against el tor cholera

Journal of Infectious Diseases

Volumn 170, Issue 6, 1994, Pages 1518-1523

  Taylor, David N ^a,b,c   Killeen, Kevin P ^a,b,c   Hack, Dallas C ^a,b,c   Kenner, Julie R ^a,b,c   Coster, Trinka S ^a,b,c   Beattie, David T ^a,b,c   Ezzell, John ^a,b,c   Hyman, Tracy ^a,b,c   Trofa, Andrew ^a,b,c   Sjogren, Maria H ^a,b,c,d   Friedlander, Arthur ^a,b,c   Mekalanos, John J ^a,b,c   Sadoff, Jerald C ^a,b,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; LIVE VACCINE;

ADULT; ARTICLE; BACTERIAL VIRULENCE; BANGLADESH; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERU; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIBRIO CHOLERAE; VIRUS STRAIN;

ADOLESCENT; ADULT; ANIMALS; ANIMALS, SUCKLING; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; FECES; FEMALE; GENES, BACTERIAL; HUMANS; IMMUNOGLOBULIN G; INTESTINES; MALE; MICE; RECOMBINATION, GENETIC; SEQUENCE DELETION; VACCINATION; VACCINES, ATTENUATED; VIBRIO CHOLERAE; VIRULENCE;

EID: 0028117638     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/170.6.1518     Document Type: Article

References (27)

1. Glass RI. Libel M. Brandling-Bennett AD. Epidemic cholera in the Americas. 1992;256:1524-5.
2. Centers for Disease Control. Cholera-Peru. MMWR 1991;40:108-10.
3. Centers for Disease Control and Prevention. Update: Cholera-Western Hemisphere, 1992. MMWR Morb Mortal Wkly Rep 1993;42:89-91.
4. World Health Organization. Cholera in 1991. Wkly Epidemiol Rec 1992;67:253-60.
5. World Health Organization. Cholera in 1992. Wkly Epidemiol Rec 1993;68:149-55.
6. Swerdlow DL. Ries AA. Cholera in the Americas-guidelines for the clinician. JAMA 1992;267:1495-9.
7. Clemens JD. Sack DA. Harris JR. et al. Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up. Lancet 1990:1:270-3.
8. Levine MM, Kaper JB, Herrington D, et al. Safely, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988;2:467-70.
9. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992;166:837-41.
10. Kotlof TKL, Wasserman SS, O’Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized. placcbo-controlled, double-blind crossover trial. Infect Immun 1992;60:4430-2.
11. Levine MM, Black RE, Clements ML, et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect lmmun 1984;43:515-22.
12. Levine MM, Kaper JB, Herrington D, et al. Volunteer studies of deletion mutants of Vibrio cholerae Ol prepared by recombinant techniques. Infect Immun 1988;56:161-7.
13. Pearson GDN, Woods A, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Proc Natl Acad Sci USA 1993;90:3750-4.
14. Roberts A, Pearson G, Mekalanos JJ. Cholera vaccine strains derived from a 1991 Peruvian isolate of Vibrio cholerae and other El Tor strains. In: Proceedings of the 28th Joint Conference, U.S.-Japan Cooperative Medical Science Program on Cholera and Related Diarrheal Diseases (Tokyo). Bethcsda, MD: National Institutes of Health, 1992.
15. Parsot C, Mekalanos JJ. Expression ofToxR, the transcriptional activator of the virulence factors in Vibrio cholerae, is modulated by the heat shock response. Proc Natl Acad Sci USA 1990;87:9898-902.
16. Parsot C. Identification of a lacZ gene in Vibrio cholerae. Res Microbiol 1992;143:27-36.
17. Herrington DA. Hall RH. Losonsky G. Mekalanos JJ. Taylor RK. Levine MM. Toxin, toxin-coregulated pili. and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 1988;168:1487-92.
18. Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci USA 1987;84:2833-7.
19. Svennerholm AM. Holmgren J, Black R, Levine M, Merson M. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis 1983;147:514-22.
20. McIntyre OR, Feeley JC. Passive serum protection of the infant rabbit against experimental cholera. J Infect Dis 1964;114:468-75.
21. Clements ML, Levine MM, Young CR, et al. Magnitude, kinetics, and duration of vibriocida! antibody response in North Americans after ingestion of Vibrio cholerae. J Infect Dis 1982;145:465-73.
22. Clemens JD, Van Loon F, Sack DA, et al. Field trial of oral cholera vaccines in Bangladesh: Serum vibriocidal and antitoxic antibodies as markers of the risk of cholcra. J Infect Dis 1991;163:1235-42.
23. Waldor MK, Mekalanos JJ. Emergence of a new cholera pandemic: Molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J Infect Dis 1994:170:278-83.
24. Tacket CO. Losonsky G. Nataro JP. et al. Safety and immunogenicity of live oral cholera vaccine candidate CVD 1 10. a Ac/.v/i Azof Aace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 1993;168:1536-40.
25. Kaper JB, Michalski J, Ketley JM, Levine MM. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect Immun 1994;62:1480-3.
26. Waldor MK, Mekalanos JJ. Vibrio cholerae O139 specific gene sequences. Lancet 1994:343:1366.
27. Cholera Working Group. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 1993;342:387-90.